Advances in the Medical Management of Vascular Anomalies

Kiersten W. Ricci

doi:10.1055/s-0037-1604297

Seminars in Interventional Radiology, Inhaltsverzeichnis

Semin intervent Radiol 2017; 34(03): 239-249
DOI: 10.1055/s-0037-1604297

Review Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Advances in the Medical Management of Vascular Anomalies

Kiersten W. Ricci

¹Division of Hematology, Hemangioma and Vascular Malformation Center, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

› Institutsangaben

Abstract

Vascular anomalies comprise a spectrum of diseases that are broadly classified as tumors and malformations. Diagnosis is often challenging, given a wide range of clinical presentations with overlapping signs and symptoms. Accurate diagnosis is critical to determine prognosis and to generate a management plan, which frequently involves multiple subspecialists during different phases of treatment. An updated classification system provides structure and clear, consistent terminology, allowing for improved diagnosis, provider communication, and collaboration. Historically, treatment of vascular anomalies was primarily surgical and medical therapies were limited or ineffective. Recent discoveries of pharmacologic agents effective in treating vascular anomalies have broadened our medical therapeutic options, limiting the need for unnecessary or high-risk procedures and improving patients' quality of life.

Keywords

vascular anomaly - vascular malformation - sirolimus - propranolol - timolol - interventional radiology

Volltext

Referenzen

References
1 Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg 1982; 69 (03) 412-422
2 International Society for the Study of Vascular Anomalies. Available at: issva.org/classification . Accessed October 23, 2016
3 Wassef M, Blei F, Adams D. , et al; ISSVA Board and Scientific Committee. Vascular anomalies classification: recommendations from the International Society for the Study of Vascular Anomalies. Pediatrics 2015; 136 (01) e203-e214
4 Dasgupta R, Fishman SJ. ISSVA classification. Semin Pediatr Surg 2014; 23 (04) 158-161
5 Mulliken JB, Burrows PE, Fishman SJ. Vascular Anomalies. 2nd ed. New York: Oxford University Press; 2013: 43-60
6 Darrow DH, Greene AK, Mancini AJ, Nopper AJ. ; Section on Dermatology, Section on Otolaryngology–Head and Neck Surgery, and Section on Plastic Surgery. Diagnosis and management of infantile hemangioma. Pediatrics 2015; 136 (04) e1060-e1104
7 Adams D, Grassia K, Mobberley-Schuman P. , et al. Clinical case series of angiosarcoma in the liver. Abstract presented at: Biannual Meeting of International Society for the Study of Vascular Anomalies; April 27–28, 2016; Buenos Aires, Argentina
8 Hoeger PH, Harper JI, Baselga E. , et al. Treatment of infantile haemangiomas: recommendations of a European expert group. Eur J Pediatr 2015; 174 (07) 855-865
9 Drolet BA, Frommelt PC, Chamlin SL. , et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics 2013; 131 (01) 128-140
10 Malik MA, Menon P, Rao KL, Samujh R. Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: a randomized controlled study. J Pediatr Surg 2013; 48 (12) 2453-2459
11 Bauman NM, McCarter RJ, Guzzetta PC. , et al. Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: a randomized clinical trial. JAMA Otolaryngol Head Neck Surg 2014; 140 (04) 323-330
12 Ábarzúa-Araya A, Navarrete-Dechent CP, Heusser F, Retamal J, Zegpi-Trueba MS. Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study. J Am Acad Dermatol 2014; 70 (06) 1045-1049
13 Ji Y, Wang Q, Chen S. , et al. Oral atenolol therapy for proliferating infantile hemangioma: a prospective study. Medicine (Baltimore) 2016; 95 (24) e3908
14 Pope E, Chakkittakandiyil A, Lara-Corrales I, Maki E, Weinstein M. Expanding the therapeutic repertoire of infantile haemangiomas: cohort-blinded study of oral nadolol compared with propranolol. Br J Dermatol 2013; 168 (01) 222-224
15 Chakkittakandiyil A, Phillips R, Frieden IJ. , et al. Timolol maleate 0.5% or 0.1% gel-forming solution for infantile hemangiomas: a retrospective, multicenter, cohort study. Pediatr Dermatol 2012; 29 (01) 28-31
16 Yu L, Li S, Su B. , et al. Treatment of superficial infantile hemangiomas with timolol: Evaluation of short-term efficacy and safety in infants. Exp Ther Med 2013; 6 (02) 388-390
17 Chan H, McKay C, Adams S, Wargon O. RCT of timolol maleate gel for superficial infantile hemangiomas in 5- to 24-week-olds. Pediatrics 2013; 131 (06) e1739-e1747
18 Danarti R, Ariwibowo L, Radiono S, Budiyanto A. Topical timolol maleate 0.5% for infantile hemangioma: its effectiveness compared to ultrapotent topical corticosteroids - a single-center experience of 278 cases. Dermatology 2016; 232 (05) 566-571
19 Püttgen K, Lucky A, Adams D. , et al; Hemangioma Investigator Group. Topical timolol maleate treatment of infantile hemangiomas. Pediatrics 2016; 138 (03) e20160355
20 Weibel L, Barysch MJ, Scheer HS. , et al. Topical timolol for infantile hemangiomas: evidence for efficacy and degree of systemic absorption. Pediatr Dermatol 2016; 33 (02) 184-190
21 Frommelt P, Juern A, Siegel D. , et al. Adverse events in young and preterm infants receiving topical timolol for infantile hemangioma. Pediatr Dermatol 2016; 33 (04) 405-414
22 Greenberger S, Yuan S, Walsh LA. , et al. Rapamycin suppresses self-renewal and vasculogenic potential of stem cells isolated from infantile hemangioma. J Invest Dermatol 2011; 131 (12) 2467-2476
23 Medici D, Olsen BR. Rapamycin inhibits proliferation of hemangioma endothelial cells by reducing HIF-1-dependent expression of VEGF. PLoS One 2012; 7 (08) e42913
24 Du W, Gerald D, Perruzzi CA. , et al. Vascular tumors have increased p70 S6-kinase activation and are inhibited by topical rapamycin. Lab Invest 2013; 93 (10) 1115-1127
25 Zhu JY, Zhang W, Ren JG, Chen G, Zhao YF. Characterization of endothelial microparticles induced by different therapeutic drugs for infantile hemangioma. J Cardiovasc Pharmacol 2015; 66 (03) 261-269
26 Kaylani S, Theos AJ, Pressey JG. Treatment of infantile hemangiomas with sirolimus in a patient with PHACE syndrome. Pediatr Dermatol 2013; 30 (06) e194-e197
27 North PE. Pediatric vascular tumors and malformations. Surg Pathol Clin 2010; 3 (03) 455-494
28 Berenguer B, Mulliken JB, Enjolras O. , et al. Rapidly involuting congenital hemangioma: clinical and histopathologic features. Pediatr Dev Pathol 2003; 6 (06) 495-510
29 Baselga E, Cordisco MR, Garzon M, Lee MT, Alomar A, Blei F. Rapidly involuting congenital haemangioma associated with transient thrombocytopenia and coagulopathy: a case series. Br J Dermatol 2008; 158 (06) 1363-1370
30 Andreu-Barasoain M, Naz E, Díaz M, López-Estebaranz JL. Rapidly involuting congenital hemangioma associated with transient anemia and thrombocytopenia. Int J Dermatol 2013; 52 (08) 1025-1026
31 Kulungowski AM, Alomari AI, Chawla A, Christison-Lagay ER, Fishman SJ. Lessons from a liver hemangioma registry: subtype classification. J Pediatr Surg 2012; 47 (01) 165-170
32 Roebuck D, Sebire N, Lehmann E, Barnacle A. Rapidly involuting congenital haemangioma (RICH) of the liver. Pediatr Radiol 2012; 42 (03) 308-314
33 Enjolras O, Mulliken JB, Boon LM, Wassef M, Kozakewich HP, Burrows PE. Noninvoluting congenital hemangioma: a rare cutaneous vascular anomaly. Plast Reconstr Surg 2001; 107 (07) 1647-1654
34 Nasseri E, Piram M, McCuaig CC, Kokta V, Dubois J, Powell J. Partially involuting congenital hemangiomas: a report of 8 cases and review of the literature. J Am Acad Dermatol 2014; 70 (01) 75-79
35 Weitz NA, Lauren CT, Starc TJ. , et al. Congenital cutaneous hemangioma causing cardiac failure: a case report and review of the literature. Pediatr Dermatol 2013; 30 (06) e180-e190
36 Zukerberg LR, Nickoloff BJ, Weiss SW. Kaposiform hemangioendothelioma of infancy and childhood. An aggressive neoplasm associated with Kasabach-Merritt syndrome and lymphangiomatosis. Am J Surg Pathol 1993; 17 (04) 321-328
37 Croteau SE, Liang MG, Kozakewich HP. , et al. Kaposiform hemangioendothelioma: atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals. J Pediatr 2013; 162 (01) 142-147
38 Szabo S, North PE. Histopathology and pathogenesis of vascular tumors and malformations. In: North PE, Sander T. , eds. Vascular Tumors and Developmental Malformations: Pathogenic Mechanisms and Molecular Diagnosis. New York: Springer-Verlag; 2016: 1-62
39 Foley LS, Kulungowski AM. Vascular anomalies in pediatrics. Adv Pediatr 2015; 62 (01) 227-255
40 O'Rafferty C, O'Regan GM, Irvine AD, Smith OP. Recent advances in the pathobiology and management of Kasabach-Merritt phenomenon. Br J Haematol 2015; 171 (01) 38-51
41 Kelly M. Kasabach-Merritt phenomenon. Pediatr Clin North Am 2010; 57 (05) 1085-1089
42 Drolet BA, Trenor III CC, Brandão LR. , et al. Consensus-derived practice standards plan for complicated Kaposiform hemangioendothelioma. J Pediatr 2013; 163 (01) 285-291
43 Iacobas I, Simon ML, Amir T. , et al. Decreased vascularization of retroperitoneal kaposiform hemangioendothelioma induced by treatment with sirolimus explains relief of symptoms. Clin Imaging 2015; 39 (03) 529-532
44 Wang Z, Li K, Dong K, Xiao X, Zheng S. Successful treatment of Kasabach-Merritt phenomenon arising from Kaposiform hemangioendothelioma by sirolimus. J Pediatr Hematol Oncol 2015; 37 (01) 72-73
45 Lackner H, Karastaneva A, Schwinger W. , et al. Sirolimus for the treatment of children with various complicated vascular anomalies. Eur J Pediatr 2015; 174 (12) 1579-1584
46 Oza VS, Mamlouk MD, Hess CP, Mathes EF, Frieden IJ. Role of sirolimus in advanced kaposiform hemangioendothelioma. Pediatr Dermatol 2016; 33 (02) e88-e92
47 Adams DM, Trenor III CC, Hammill AM. , et al. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics 2016; 137 (02) e20153257
48 Uno T, Ito S, Nakazawa A, Miyazaki O, Mori T, Terashima K. Successful treatment of Kaposiform hemangioendothelioma with everolimus. Pediatr Blood Cancer 2015; 62 (03) 536-538
49 Matsumoto H, Ozeki M, Hori T. , et al. Successful everolimus treatment of kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: clinical efficacy and adverse effects of mTOR inhibitor therapy. J Pediatr Hematol Oncol 2016; 38 (08) e322-e325
50 Ishikawa K, Hatano Y, Ichikawa H, Hashimoto H, Fujiwara S. The spontaneous regression of tufted angioma. A case of regression after two recurrences and a review of 27 cases reported in the literature. Dermatology 2005; 210 (04) 346-348
51 Chiu YE, Drolet BA, Blei F. , et al. Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon. Pediatr Blood Cancer 2012; 59 (05) 934-938
52 Lanöel A, Torres Huamani AN, Feliú A, Lubieniecki F, Galluzzo L, Cervini AB. Treatment of kaposiform hemangioendothelioma and tufted angioma with sirolimus, a case clinical series. Abstract presented at: Biannual Meeting of International Society for the Study of Vascular Anomalies; April 27–28, 2016; Buenos Aires, Argentina
53 Swetman GL, Berk DR, Vasanawala SS, Feinstein JA, Lane AT, Bruckner AL. Sildenafil for severe lymphatic malformations. N Engl J Med 2012; 366 (04) 384-386
54 Singh P, Singh P, Mundy D. Giant neonatal thoraco-abdominal lymphatic malformations treated with sildenafil: a case report and review of the literature. J Neonatal Perinatal Med 2013; 6 (01) 89-92
55 Danial C, Tichy AL, Tariq U. , et al. An open-label study to evaluate sildenafil for the treatment of lymphatic malformations. J Am Acad Dermatol 2014; 70 (06) 1050-1057
56 Koshy JC, Eisemann BS, Agrawal N, Pimpalwar S, Edmonds JL. Sildenafil for microcystic lymphatic malformations of the head and neck: a prospective study. Int J Pediatr Otorhinolaryngol 2015; 79 (07) 980-982
57 Margolin JF, Soni HM, Pimpalwar S. Medical therapy for pediatric vascular anomalies. Semin Plast Surg 2014; 28 (02) 79-86
58 Huber S, Bruns CJ, Schmid G. , et al. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int 2007; 71 (08) 771-777
59 Hammill AM, Wentzel M, Gupta A. , et al. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer 2011; 57 (06) 1018-1024
60 Kim D, Benjamin L, Wysong A, Hovsepian D, Teng J. Treatment of complex periorbital venolymphatic malformation in a neonate with a combination therapy of sirolimus and prednisolone. Dermatol Ther (Heidelb) 2015; 28 (04) 218-221
61 Akyüz C, Ataş E, Varan A. Treatment of a tongue lymphangioma with sirolimus after failure of surgical resection and propranolol. Pediatr Blood Cancer 2014; 61 (05) 931-932
62 Vlahovic AM, Vlahovic NS, Haxhija EQ. Sirolimus for the treatment of a massive capillary-lymphatico-venous malformation: a case report. Pediatrics 2015; 136 (02) e513-e516
63 Ricci K, Hammill AM, Trenor III CC. , et al. Retrospective and prospective results of the use of sirolimus in the treatment of generalized lymphatic anomaly and Gorham Stout disease. Abstract presented at: Biannual Meeting of International Society for the Study of Vascular Anomalies; April 27–28, 2016; Buenos Aires, Argentina
64 Triana P, Dore M, Cerezo VN. , et al. Sirolimus in the treatment of vascular anomalies. Eur J Pediatr Surg 2017; 27 (01) 86-90
65 Wang Z, Li K, Yao W, Dong K, Xiao X, Zheng S. Successful treatment of kaposiform lymphangiomatosis with sirolimus. Pediatr Blood Cancer 2015; 62 (07) 1291-1293
66 Ivars M, Redondo P. Efficacy of topical sirolimus (Rapamycin) for the treatment of microcystic lymphatic malformations. JAMA Dermatol 2017; 153 (01) 103-105
67 Yuksekkaya H, Ozbek O, Keser M, Toy H. Blue rubber bleb nevus syndrome: successful treatment with sirolimus. Pediatrics 2012; 129 (04) e1080-e1084
68 Salloum R, Fox CE, Alvarez-Allende CR. , et al. Response of blue rubber bleb nevus syndrome to sirolimus treatment. Pediatr Blood Cancer 2016; 63 (11) 1911-1914
69 Boscolo E, Limaye N, Huang L. , et al. Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects. J Clin Invest 2015; 125 (09) 3491-3504
70 Boon LM, Hammer J, Duez S. , et al. Rapamycin as novel treatment for refractory to standard care venous malformations. Abstract presented at: Biannual Meeting of International Society for the Study of Vascular Anomalies; April 27–28, 2016; Buenos Aires, Argentina
71 Ricci K, Hammill AM, Trenor III CC. , et al. Retrospective and prospective results of sirolimus in the treatment of capillary lymphatic venous malformations. Abstract presented at: Annual Conference of American Society of Pediatric Hematology Oncology; May 2016; Minneapolis, MN
72 Griffin Jr TD, Foshee JP, Finney R, Saedi N. Port wine stain treated with a combination of pulsed dye laser and topical rapamycin ointment. Lasers Surg Med 2016; 48 (02) 193-196
73 Marqués L, Núñez-Córdoba JM, Aguado L. , et al. Topical rapamycin combined with pulsed dye laser in the treatment of capillary vascular malformations in Sturge-Weber syndrome: phase II, randomized, double-blind, intraindividual placebo-controlled clinical trial. J Am Acad Dermatol 2015; 72 (01) 151-158.e1
74 Nelson JS, Jia W, Phung TL, Mihm Jr MC. Observations on enhanced port wine stain blanching induced by combined pulsed dye laser and rapamycin administration. Lasers Surg Med 2011; 43 (10) 939-942
75 Skaro AI, Marotta PJ, McAlister VC. Regression of cutaneous and gastrointestinal telangiectasia with sirolimus and aspirin in a patient with hereditary hemorrhagic telangiectasia. Ann Intern Med 2006; 144 (03) 226-227
76 Ozeki M, Hori T, Kanda K. , et al. Everolimus for primary intestinal lymphangiectasia with protein-losing enteropathy. Pediatrics 2016; 137 (03) e20152562
77 Cirulli A, Liso A, D'Ovidio F. , et al. Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia. Acta Haematol 2003; 110 (01) 29-32
78 Junquera F, Saperas E, de Torres I, Vidal MT, Malagelada JR. Increased expression of angiogenic factors in human colonic angiodysplasia. Am J Gastroenterol 1999; 94 (04) 1070-1076
79 Han C, Choe SW, Kim YH. , et al. VEGF neutralization can prevent and normalize arteriovenous malformations in an animal model for hereditary hemorrhagic telangiectasia 2. Angiogenesis 2014; 17 (04) 823-830
80 Li Y, Fu S, Chen H. , et al. Inhibition of endothelial Slit2/Robo1 signaling by thalidomide restrains angiogenesis by blocking the PI3K/Akt pathway. Dig Dis Sci 2014; 59 (12) 2958-2966
81 Blinc A, Golli T, Vodnik AC, Zver S. Concurrent thalidomide and radiation therapy for extensive arterio-venous malformations. Thromb Haemost 2008; 99 (01) 235-237
82 Geisthoff UW, Nguyen HL, Röth A, Seyfert U. How to manage patients with hereditary haemorrhagic telangiectasia. Br J Haematol 2015; 171 (04) 443-452
83 Thalgott J, Dos-Santos-Luis D, Lebrin F. Pericytes as targets in hereditary hemorrhagic telangiectasia. Front Genet 2015; 6: 37
84 Ardelean DS, Letarte M. Anti-angiogenic therapeutic strategies in hereditary hemorrhagic telangiectasia. Front Genet 2015; 6: 35
85 Bauditz J. Effective treatment of gastrointestinal bleeding with thalidomide--Chances and limitations. World J Gastroenterol 2016; 22 (11) 3158-3164
86 Lebrin F, Srun S, Raymond K. , et al. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med 2010; 16 (04) 420-428
87 Ge ZZ, Chen HM, Gao YJ. , et al. Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation. Gastroenterology 2011; 141 (05) 1629-1637.e1 , 4
88 Franchini M, Frattini F, Crestani S, Bonfanti C. Novel treatments for epistaxis in hereditary hemorrhagic telangiectasia: a systematic review of the clinical experience with thalidomide. J Thromb Thrombolysis 2013; 36 (03) 355-357
89 Bowcock SJ, Patrick HE. Lenalidomide to control gastrointestinal bleeding in hereditary haemorrhagic telangiectasia: potential implications for angiodysplasias?. Br J Haematol 2009; 146 (02) 220-222
90 Samour M, Saygin C, Abdallah R, Kundu S, McCrae KR. Pomalidomide in hereditary hemorrhagic telangiectasia: interim results of a phase I study. Blood 2016; 128: 210
91 Simonds J, Miller F, Mandel J, Davidson TM. The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 2009; 119 (05) 988-992
92 Davidson TM, Olitsky SE, Wei JL. Hereditary hemorrhagic telangiectasia/avastin. Laryngoscope 2010; 120 (02) 432-435
93 Chen IV S, Karnezis T, Davidson TM. Safety of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope 2011; 121 (03) 644-646
94 Karnezis TT, Davidson TM. Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope 2011; 121 (03) 636-638
95 Rohrmeier C, Sachs HG, Kuehnel TS. A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia. Eur Arch Otorhinolaryngol 2012; 269 (02) 531-536
96 Dupuis-Girod S, Ambrun A, Decullier E. , et al. Effect of Bevacizumab nasal spray on epistaxis duration in hereditary hemorrhagic telangiectasia: a randomized clinical trial. JAMA 2016; 316 (09) 934-942
97 Dupuis-Girod S, Ginon I, Saurin JC. , et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA 2012; 307 (09) 948-955
98 Arizmendez NP, Rudmik L, Poetker DM. Intravenous bevacizumab for complications of hereditary hemorrhagic telangiectasia: a review of the literature. Int Forum Allergy Rhinol 2015; 5 (11) 1042-1047